Transpositional immunity: immunotherapeutical approach against bovine leukemia virus by Roa-Castellanos, RA
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
Retrovirology
Open Access Poster presentation
Transpositional immunity: immunotherapeutical approach against 
bovine leukemia virus
RA Roa-Castellanos
Address: Faculty of veterinary medicine, La Salle University, Instituto de Bioetica, Pontificia Universidad Javeriana, Bogota DC, Colombian 
National Health Instiute, Colombian National Insitute of Cancerology, Colombia
Bovine Leukemia Virus, an unparalleled oncogenic retro-
virus related taxonomically to HTLV and HIV, was diag-
nosed using Agar Gel Immunodiffusion (AGID) among
485 Holstein cows older than two years in five herds
across the northwest of the Bogotá valley. Real serological
prevalence of BLV infection varied from 68% to 89%,
finding similar frequencies to those encountered in dairy
regions of the USA and Canada. The leukemic condition
of B1 cells (CD5+) called Persistent Lymphocytosis (PL)
was confirmed by carrying out White Blood Cells Counts
(WBC) in seropositive animals for three months after tak-
ing initial samples. 56 seropositive individuals (11.55%)
exhibited notorious PL. Only 51 animals were eventually
selected to from the group to be evaluated. The group of
51 animals was divided into two subgroups. Subgroup 1,
which comprised 11 control animals, did not receive any
treatment. The second group, 40 experimental cows, was
given three types of Th1/Th3-immune response-stimu-
lant, previously selected during the first phase of the
investigation. 78% of the experimental group developed
slight hyperthermia (40°C +/- 1°C). These animals
obtained normalization of their blood values, as far as 75
days after-treatment when the experiment was over. In
contrast, those experimental cows that did not show any
thermic increase or that did not receive complete treat-
ment, in spite of recovering temporarily, returned to the
leukemic status. A case of incipient retroorbitary lympho-
sarcoma, confirmed by histopathology, was submitted to
therapy. The growth rate of this tumor decreased substan-
tially in comparison with two untreated cases suffering
from comparable presentations; at the extent that one year
after therapy the tumor maintained practically the same
size. These results suggest that 1) Antagonistic cytokine
dynamics (e.g.Th2 cellular system predominance over
Th1 and Th3 system) involved in pathogenesis of these
retroviral presentations, as well as their initial forms of
neoplasia, may be reversed to protract expectancy of life in
afflicted patients. 2) Interestingly, different manifesta-
tions of BL caused by BLV such as asymptomatic stadium,
PL, and Lymphosarcoma - also seen in other retroviral
infections in different species - seem to be consecutive
stages along an only process. Considering the foregoing,
the length of each presentation would be chiefly deter-
mined by means of inherited MHC dominance and its
subproducts (Interleukins, chemokines, Inmunoglobu-
lins, cell receptors involved, etc.) in every individual
response against retroviruses. 3) Extracorporeal systems of
hyperthermia might not exert the same response on viral
reservoirs as this procedure does through Heat Shock Pro-
teins (HSP) molecules and Th1/Th3 exacerbation. To gen-
erate an effective response against this imperceptible
agent (BLV), which is using a Trojan horse-like mecha-
nism to go unnoticed before the immune system; it is nec-
essary to stimulate NK and γδ cells via IFN-γ/α, IL-1, IL-2,
IL-12, IL-15, TNF-α, MHC I/MHC III, Cortisol and HSPs.
4) This type of therapy, called as Transpositional Immu-
nity, would strengthen epidemiological strategies to fight
BLV infection; moreover, it could be seen as an animal
model for similar human and non-ruminant illnesses.
Resembling Hairy Cell Leukemia and Chronic Lym-
phocytic Leukemia in humans, including its Ritcher's syn-
drome, and being recently associated with Human Breast
Cancer in addition to Lymphoma in chimpanzees fed on
BLV infected milk; BLV cannot be ruled out as a carcino-
gen zoonotic agent yet.
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